COMMUNIQUÉS West-GlobeNewswire

Helsinn and MEI Pharma Announce Publication of Phase II Data for Pracinostat in Combination with Azacitidine in Blood Advances
14/02/2019
Helsinn and MEI Pharma Announce Publication of Phase II Data for Pracinostat in Combination with Azacitidine in the Frontline Treatment of Older AML Patients Unfit for Intensive Chemotherapy, in Blood Advances Lugano, [...]
Physeon’s Veinplicity Device Featured on ABC Affiliate KSTP Channel 5
14/02/2019
“VIVA” Trial Enrolling at Mayo Clinic SCHAFFHAUSEN, Switzerland, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Physeon GmbH, (“Physeon” or the “Company”), a leading developer of medical technology products for venous access, today [...]
Rafina Innovations Begins Development on a Prototype for Sleep Apnoea
14/02/2019
GLASGOW, SCOTLAND, Feb. 14, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Rafina Innovations Inc. ("the Company" (OTCQB: VICA)) is delighted to announce that it recently commenced development on a prototype for sleep [...]
PLx Pharma Inc. Announces Adjournment of Special Meeting of Stockholders
14/02/2019
HOUSTON, Feb. 14, 2019 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“ PLx ” or the “ Company ”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Vazalore™ [...]
PSIQ Enters the Projected $ 60 Billion Global Kosher Food Market
14/02/2019
SUNRISE, Fla., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Solutions, Inc. (OTC Pink: PSIQ), through its subsidiary Elite Products International, Inc., announces it has granted distribution rights to IT Distributions, LLC. to [...]
Coherus BioSciences to Report Fourth Quarter and Full Year 2018 Financial Results on February 28th
14/02/2019
REDWOOD CITY, Calif., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that its fourth quarter and full year 2018 financial results will be released after market close on [...]
Lundbeck and Otsuka report phase III data evaluating brexpiprazole for the treatment of manic episodes associated with bipolar I disorder
14/02/2019
The efficacy of brexpiprazole for the acute treatment of manic episodes, with or without mixed features, in subjects with bipolar I disorder was investigated in two three-week, double-blind, placebo-controlled trials [...]
Umbrellux DAO Provides Solution to Americans Who Thought They Had an Allergy, but Really Suffer from Histamine Intolerance
14/02/2019
ANN ARBOR, Mich., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Only 10 percent of Americans have food allergies, but according to a new study in JAMA Network Open , almost double the number believe they do. Could the other half [...]
Cannabis Beverages Coming Soon! Which of These 4 Brands Will Be on Store Shelves First?
14/02/2019
VANCOUVER, British Columbia, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Mugglehead says cannabis beverages are going to be the talk of 2019. With Canada set to legalize edibles and the U.S. recently passing the Farm Bill, both [...]
Radius Health to Announce Fourth Quarter and Full Year 2018 Financial Results, Host Conference Call and Live Webcast on Thursday, February 28, 2019
14/02/2019
WALTHAM, Mass., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq: RDUS) announced today that it will release its fourth quarter and full year 2018 financial results on Thursday, February 28, 2019. The Company [...]
NovuHealth Data Showcases the Value of Annual Wellness Visits for Medicare and Medicaid Members
14/02/2019
Data Confirm That AWVs Serve as an Important Gateway, as Those Who Receive One Are Up To 10 Times More Likely to Complete Other High-Value Healthcare Activities MINNEAPOLIS, Feb. 14, 2019 (GLOBE NEWSWIRE) -- NovuHealth [...]
Eloxx Pharmaceuticals to Present at the 8th Annual SVB Leerink Global Healthcare Conference in New York City on Friday, March 1, 2019
14/02/2019
WALTHAM, Mass., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic [...]
Tauriga Sciences Inc. Taking Concrete Steps to Sell Tauri-Gum™ on Amazon
14/02/2019
New York, NY, Feb. 14, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), engaged in building its business through the development, distribution, and [...]
Sarepta Announces FDA Acceptance of Golodirsen (SRP-4053) New Drug Application for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 53
14/02/2019
-- FDA Grants Priority Review Status -- -- Regulatory Action Date is August 19, 2019 -- -- Golodirsen has been studied for the treatment of exon 53 amenable patients, approximately eight percent of patients with [...]
Assure Holdings Closes $3 Million Loan Facility
14/02/2019
New Agreement Features $2 Million Term Loan and $1 Million Line of Credit to Help Fund Expansion DENVER, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “ Company ” or “ Assure ”) (TSXV: IOM; OTCPK: ARHH), [...]
American Cannabis Company, Inc. Announces Hemp Business Development & Appointment of Chief Operations Officer
14/02/2019
DENVER, CO, Feb. 14, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- American Cannabis Company, Inc. (OTCQB: AMMJ) (“ACC”), a full-service business-to-business consulting solutions provider, and seller of ancillary [...]
Achaogen Submits Response to ASPR/BARDA Request for Information (RFI) for Antimicrobial Resistance Project BioShield
14/02/2019
-- Plazomicin may be well-suited to play a critical role in biodefense preparedness -- SOUTH SAN FRANCISCO, Calif., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company [...]
Achaogen Provides Update on Corporate Progress and Key Preliminary Fourth Quarter 2018 Results
14/02/2019
-- Company provides update on ZEMDRI ® commercialization and launch -- -- Data from both the EPIC and CARE Phase 3 clinical studies of plazomicin are expected in peer-reviewed publication -- SOUTH SAN FRANCISCO, Calif [...]
Ultragenyx and Kyowa Kirin Announce Positive 64-Week Results for Crysvita® (burosumab) from Phase 3 Study in Children with X-linked Hypophosphatemia (XLH)
14/02/2019
Results Confirm and Extend 40-Week Findings that Treatment with Crysvita is Superior to Conventional Therapy NOVATO, Calif., TOKYO and LONDON, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: [...]

Pages